Dr. Chang is Assistant Professor, Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tenn. He has received a research grant from Amgen and Cytogen, and is on the Speaker's Bureaus of Novartis and Sanofi.
Cost considerations in the management of bladder cancer
"We will review the evidence and identify potential areas of improvement that can help reduce costs associated with UCB management while improving outcomes," write Daniel J. Lee, MD, and Sam S. Chang, MD.
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment
EFS benefit is seen with sasanlimab in CIS and T1 NMIBC
Perioperative sacituzumab govitecan/pembro yields compelling CR rate in MIBC
Interim ENLIGHTED data show promise for padeliporfin VTP therapy in UTUC